NCT05532735View on ClinicalTrials.gov

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

July 17, 2024

Study Completion Date

November 11, 2024

Conditions
Retinal Vein Occlusion
Interventions
BIOLOGICAL

ANXV

ANXV (Human recombinant Annexin A5 protein)

Trial Locations (7)

20186

Virginia Retina Center, Warrenton

21740

Cumberland Valley Retina Consultants, Hagerstown

71219

Eye Associates of Northeast Louisiana, West Monroe

74114

Tulsa Retina Consultants, Tulsa

77401

Retina Consultants of Texas, Bellaire

78240

Retina Consultants of Texas, San Antonio

78503

Valley Retina Institute, McAllen

Sponsors

Collaborators (1)

InFocus Clinical Research
All Listed Sponsors
collaborator

InFocus Clinical Research

INDUSTRY

lead

Annexin Pharmaceuticals AB

INDUSTRY

NCT05532735 - Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter